U.S. Genotyping Market to Surge USD 26.53 Billion by 2034 at 13.72% CAGR [Yahoo! Finance]
Bio-Rad Laboratories, Inc. Class A (BIO)
Last bio-rad laboratories, inc. class a earnings: 2/13 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
bio-rad.com/en-us/corporate/investor-relations
Company Research
Source: Yahoo! Finance
Ottawa, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The U.S. genotyping market size was valued at USD 7.33 billion in 2024 and is predicted to hit around USD 26.53 billion by 2034, rising at a 13.72% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research. The U.S. genotyping market is driven by its expanding healthcare applications, increasing research and development, and growing incidences of chronic diseases. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5160 Key Takeaways By product, the reagents & kits segment held the major revenue share of 62% in the U.S. genotyping market in 2023. By product, the services segment is expected to grow significantly at a CAGR of 13.62% during the forecast period. By technology, the sequencing segment held a 23% share in the market in 2023. By technology, the PCR segment is expected to grow significantly durin
Show less
Read more
Impact Snapshot
Event Time:
BIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIO alerts
High impacting Bio-Rad Laboratories, Inc. Class A news events
Weekly update
A roundup of the hottest topics
BIO
News
- Bio-Rad Laboratories (NYSE:BIO) was downgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c-)" rating to a "sell (d-)" rating.MarketBeat
- Bio-Rad Laboratories (NYSE:BIO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street ZMarketBeat
- Bio-Rad Laboratories (NYSE:BIO) had its price target raised by analysts at Citigroup Inc. from $350.00 to $375.00. They now have a "buy" rating on the stock.MarketBeat
- Bio-Rad Laboratories (NYSE:BIO) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d+)" rating to a "hold (c-)" rating.MarketBeat
- Bio-Rad Laboratories (NYSE:BIO) had its price target raised by analysts at Wells Fargo & Company from $265.00 to $340.00. They now have an "equal weight" rating on the stock.MarketBeat
BIO
Earnings
- 10/29/25 - Miss
BIO
Sec Filings
- 12/2/25 - Form 144
- 11/18/25 - Form 144
- 11/10/25 - Form 4
- BIO's page on the SEC website